AZURRX BIOPHARM (NASDAQ: AZRX) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for AZURRX BIOPHARM and Theravance Biopharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AZURRX BIOPHARM 0 0 2 0 3.00
Theravance Biopharma 1 0 5 0 2.67

AZURRX BIOPHARM presently has a consensus price target of $7.50, indicating a potential upside of 151.68%. Theravance Biopharma has a consensus price target of $42.67, indicating a potential upside of 48.30%. Given AZURRX BIOPHARM’s stronger consensus rating and higher probable upside, equities analysts plainly believe AZURRX BIOPHARM is more favorable than Theravance Biopharma.

Institutional & Insider Ownership

6.1% of AZURRX BIOPHARM shares are owned by institutional investors. Comparatively, 84.5% of Theravance Biopharma shares are owned by institutional investors. 9.1% of AZURRX BIOPHARM shares are owned by company insiders. Comparatively, 6.1% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares AZURRX BIOPHARM and Theravance Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AZURRX BIOPHARM N/A N/A -216.05%
Theravance Biopharma -1,604.87% -99.43% -47.10%

Valuation and Earnings

This table compares AZURRX BIOPHARM and Theravance Biopharma’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
AZURRX BIOPHARM N/A N/A -$14.59 million N/A N/A
Theravance Biopharma $48.65 million 31.99 -$190.66 million ($5.17) -5.56

AZURRX BIOPHARM has higher revenue, but lower earnings than Theravance Biopharma.

Summary

AZURRX BIOPHARM beats Theravance Biopharma on 6 of the 10 factors compared between the two stocks.

AZURRX BIOPHARM Company Profile

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

Theravance Biopharma Company Profile

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Receive News & Ratings for AZURRX BIOPHARM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AZURRX BIOPHARM and related companies with MarketBeat.com's FREE daily email newsletter.